The HCPLive Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.
March 28th 2024
The investigators seek to replicate the data in a future randomized control trial, and they hope to compare biofeedback to different therapies such as pulmonary rehabilitation.
2024 USCAP Satellite Symposia
March 25-27, 2024
Register Now!
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Community Practice Connections™: Guidebook for Community Oncology NSCLC Treating Teams to Administer EGFR Exon 20-Targeted Regimens
View More
1st Annual Hawaii Lung: A Multidisciplinary Case-Based Conference™
View More
Advances In™ KRAS Inhibition: Modern Considerations In Targeting KRAS-Mutated Lung, Colorectal, And Pancreatic Cancers
View More
How We Do It™: Integrating Gene Fusion Testing in Oncology Clinics for Patients with NSCLC
View More
Revolutionizing Early-Stage NSCLC Treatment: Pathologists’ Key Insights into Predicting Pathologic Responses to Immunotherapies
View More
Community Practice Connections™: 20th Annual Winter Lung Conference
View More
Medical Crossfire®: Key Strategies to Prioritize Testing and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Respiratory Syncytial Virus: Understanding the Infection Burden and Anticipating the Impact of Vaccines
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Engaging the Multidisciplinary Care Team to Optimize Care of Patients With EGFR Mutation–Positive NSCLC: A Lung Cancer Tumor Board
View More
25th Annual International Lung Cancer Congress®
July 25-27, 2024
Register Now!
24th Annual International Lung Cancer Congress®
View More
Engaging the Multidisciplinary Care Team to Optimize Care of Patients With EGFR Mutation-Positive NSCLC: A Lung Cancer Tumor Board
View More
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Advances In™: Aligning Pathology and Oncology Efforts in the Community to Improve NSCLC Care
View More
Community Practice Connections: 7th Annual School of Nursing Oncology™
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
6th Annual Advanced Practice Collaborative
View More
Community Practice Connections™: 24th Annual International Lung Cancer Congress®
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
19th Annual New York Lung Cancers Symposium®
November 16, 2024
Register Now!
Let’s Get “Real”: Alpha-1 Antitrypsin Deficiency—Case-Based Perspectives on Managing Associated Emphysema
View More
Shaping the Management of COPD with Biologic Therapy
View More
Nintedanib Treatment Slows Disease Progression in Patients with Idiopathic Pulmonary Fibrosis
May 21st 2014Results from two studies show that treatment with the novel kinase inhibitor nintedanib significantly slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF). However, only one study showed nintedanib had any effect on slowing deterioration in quality of life or reducing the risk of a first acute exacerbation compared with placebo.
Pirfenidone Improves Survival in Idiopathic Pulmonary Fibrosis
May 21st 2014Recently published study results, when combined with results from previous clinical trials, show treatment with the antifibrotic drug pirfenidone slows disease progression and improves survival in patients with idiopathic pulmonary fibrosis (IPF). These findings, if they lead the FDA to reevaluate and approve this drug, could be a game changer for patients with IPF, a disease marked by a high mortality rate and few treatment options.
AUGMENT Study Results Show Combination Therapy Superior to Monotherapy for COPD
May 20th 2014Treatment with a fixed-dose combination of aclidinium 400 µg and formoterol 12 µg significantly improved bronchodilation in patients with moderate to severe COPD compared with aclidinium or formoterol monotherapy alone.
Rosuvastatin Treatment Does Not Improve Lung Function in Patients with COPD
May 19th 2014Study results presented at the 2014 American Thoracic Society International Conference show that treatment with rosuvastatin reduces markers of inflammation in patients with COPD after 12 weeks, but is not associated with improvements in measures of lung function.
Simvastatin Does Not Affect Exacerbation Rates in High-Risk Patients with COPD
May 19th 2014Study results presented at the 2014 American Thoracic Society International Conference show that treatment with simvastatin did not decrease exacerbation rates or time to first exacerbation in patients with COPD.
Consider Reinfusing Autologous Blood Lost During Cardiac Bypass Surgery
May 15th 2014Since those who undergo cardiac surgery are more likely to receive allogeneic blood transfusions, researchers at Johns Hopkins Hospital set out to investigate the effects of reinfusing autologous blood lost during cardiopulmonary bypass.
Sublingual Immunotherapy Reduces Symptoms of Asthma, Allergic Rhinoconjunctivitis
May 13th 2014With the US Food and Drug Administration's recent approval of 2 sublingual immunotherapies for allergic rhinitis with or without conjunctivitis, US physicians no longer have to pursue the off-label use of these treatments.